Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

inhibitor

inhibitor is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 171
News articles 0
Drug details — inhibitor
Class
—
Route
—
Patents
20
Programs
171
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

inhibitor is an FDA-listed pharmaceutical active ingredient.

Key facts

INN inhibitor

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. 090701 Phase 3 · Takeda · Hemophilia A or B With Inhibitors
  2. 090701 Phase 3 · Baxalta Innovations · Hemophilia A or B With Inhibitors
  3. APHP180596 Phase 3 · PARItec · antibiotic therapy in Sepsis
  4. APHP211034 Phase 3 · PARItec · patients hospitalized in ICU with ESBL-producing Enterobacte
  5. APHP220763 Phase 3 · PARItec · Catheter related bloodstream infections due to Staphylococcu
  6. APHP220814 Phase 3 · PARItec · Community-acquired pneumonia
  7. Aromatase Inhibitors Phase 3 · United Therapeutics Europe · Breast Cancer
  8. BB2121-MM-003 Phase 3 · Celgene · Multiple myeloma (MM) with at least 2 prior therapies includ

Related patents

Browse patents

  1. AU 2024384453

    CITRATE COORDINATION COMPLEX OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF

    Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. PT 3886798

    COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF

    Expires Wed Apr 11 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 20260083736

    GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS FOR USE IN THE TREATMENT OF SUBSTANCE USE DISORDER IN PATIENTS WITH HIGH IMPULSIVITY

    Expires Wed Mar 21 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 20260060930

    New crystalline Forms, new pharmaceutical Composition and Dose Regimen of a Dipeptidyl peptidase I inhibitor for the Treatment of Patients with Bronchiectasis or other DPP-I mediated Diseases

    Expires Wed Feb 28 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 20260055120

    Bicyclic pyrimidinones as inhibitors of NOX4

    Expires Wed Feb 21 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 20260008777

    INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE

    Expires Wed Jan 03 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 20260001878

    SUBSTITUTED PYRROLOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF TLR9

    Expires Wed Dec 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 2025333394

    Tiparp Inhibitor Compounds

    Expires Wed Oct 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. EP 4640274

    LPAR1-INHIBITOREN

    Expires Tue Oct 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 2025304535

    KAT6 Inhibitors

    Expires Wed Sep 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12428379

    Acylsulfonamide KAT6A inhibitors

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12428416

    ERK inhibitors and uses thereof

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12428415

    Matriptase 2 inhibitors and uses thereof

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12428395

    Heterocyclic compounds as kinase inhibitor and uses thereof

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12421269

    SGLT2/DPP4 inhibitor and application thereof

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12421231

    Azaindole derivatives and their use as ERK kinase inhibitors

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12421236

    Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12419890

    Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12421273

    Ectonucleotidase inhibitors and methods of use thereof

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12421228

    Naphthyridine derivatives as PRC2 inhibitors

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is inhibitor?

inhibitor is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.